3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Polycythemia Vera
6
Thrombocythemia, Essential
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Myeloproliferative Disorders
2
Melanoma
2
Solid Cancers
1
Skin Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome
1
Neoplasms
1
Neoplasm of Uncertain Malignant Potential
1
Neoplasm Metastasis
1
Leukemia, Myeloid, Acute
1
Hepatitis C, Chronic
1
Glioma
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Blast Crisis
1
Interventions
Imatinib Mesylate
13
bosutinib
3
Vincristine
3
Dexamethasone
3
Dasatinib
3
Cyclophosphamide
3
nilotinib
2
fludarabine phosphate
2
fludarabine
2
Methotrexate
2
Daunorubicin
2
Cytarabine
2
Azacitidine
2
Acetaminophen
2
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
2
venetoclax
1
thymoglobulin
1
peginterferon alfa-2a
1
flumatinib
1
Whole-Body Irradiation
1
Tyrosine Kinase Inhibitors
1
Tacrolimus
1
Rituximab
1
Prednisone
1
Prednisolone
1
Mycophenolic Acid
1
Mitoxantrone
1
Mercaptopurine
1
Melphalan
1
Magnetic Resonance Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Philadelphia Chromosome
×
peginterferon alfa-2a
×
Clear all
NCT00763763
2011-10-05
AFR07
Assistance Publique - Hôpitaux de Paris
Phase 2
Completed
55 enrolled